CY1116925T1 - Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια - Google Patents

Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια

Info

Publication number
CY1116925T1
CY1116925T1 CY20151100824T CY151100824T CY1116925T1 CY 1116925 T1 CY1116925 T1 CY 1116925T1 CY 20151100824 T CY20151100824 T CY 20151100824T CY 151100824 T CY151100824 T CY 151100824T CY 1116925 T1 CY1116925 T1 CY 1116925T1
Authority
CY
Cyprus
Prior art keywords
relaxin
acute heart
acute
heart deficiency
education
Prior art date
Application number
CY20151100824T
Other languages
Greek (el)
English (en)
Inventor
Elaine Unemori
Sam L Teichman
Gad Cotter
Dennis R Stewart
Martha Jo Whitehouse
Original Assignee
Corthera, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corthera, Inc. filed Critical Corthera, Inc.
Publication of CY1116925T1 publication Critical patent/CY1116925T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20151100824T 2008-05-16 2015-09-18 Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια CY1116925T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US19054508P 2008-08-28 2008-08-28
US20124008P 2008-12-08 2008-12-08
US16433309P 2009-03-27 2009-03-27
EP09747740.0A EP2288373B1 (en) 2008-05-16 2009-05-15 Relaxin for use in treating of dyspnea associated with acute heart failure

Publications (1)

Publication Number Publication Date
CY1116925T1 true CY1116925T1 (el) 2017-04-05

Family

ID=40834101

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100824T CY1116925T1 (el) 2008-05-16 2015-09-18 Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια

Country Status (30)

Country Link
US (7) US8053411B2 (https=)
EP (2) EP2288373B1 (https=)
JP (4) JP5651586B2 (https=)
CN (3) CN102036679A (https=)
AR (1) AR071810A1 (https=)
AU (1) AU2009246114B2 (https=)
BR (1) BRPI0913011A2 (https=)
CA (1) CA2724540C (https=)
CR (1) CR11749A (https=)
CY (1) CY1116925T1 (https=)
DK (1) DK2288373T3 (https=)
EA (2) EA201500552A1 (https=)
ES (1) ES2546287T3 (https=)
GB (2) GB2459983B (https=)
HK (1) HK1202054A1 (https=)
HR (1) HRP20150845T1 (https=)
HU (1) HUE025483T2 (https=)
IL (3) IL208992A (https=)
MA (1) MA32389B1 (https=)
MX (1) MX2010012450A (https=)
MY (2) MY159803A (https=)
NZ (3) NZ589009A (https=)
PL (1) PL2288373T3 (https=)
PT (1) PT2288373E (https=)
SG (2) SG10201609580YA (https=)
SI (1) SI2288373T1 (https=)
TW (1) TWI386202B (https=)
UA (1) UA99953C2 (https=)
WO (1) WO2009140659A2 (https=)
ZA (1) ZA201007449B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0912559A2 (pt) * 2008-05-16 2015-10-13 Corthera Inc método de tratar insuficiência cardíaca crônica
CA2724540C (en) 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
EP2544706B1 (en) 2010-03-10 2015-06-17 The University Of Melbourne Modulating aquaporins with relaxin
US9465039B2 (en) 2010-08-06 2016-10-11 Mycartis Nv Perlecan as a biomarker for renal dysfunction
EA030886B1 (ru) * 2010-08-17 2018-10-31 Амбркс, Инк. Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
RU2014103288A (ru) * 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
AU2013202269A1 (en) * 2011-10-26 2013-05-16 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
CA2864100A1 (en) * 2012-02-14 2013-08-22 The Regents Of The University Of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
US9452973B2 (en) 2012-05-04 2016-09-27 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Modulators of the relaxin receptor 1
KR102299073B1 (ko) * 2012-10-26 2021-09-09 치에시 파마슈티시 에스.피.아. 심부전에서 혈압을 조절하고 호흡곤란을 감소시키는 방법
PT2981258T (pt) * 2013-04-05 2020-10-19 Scpharmaceuticals Inc Formulações farmacêuticas para administração subcutânea de furosemida
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
MX2016010087A (es) * 2014-02-03 2016-10-07 Novartis Ag Filtros para equipos de infusion.
EP2946788A1 (en) * 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
US20170100460A1 (en) * 2014-06-13 2017-04-13 Novartis Ag Use of serelaxin to reduce gdf-15
PT3387019T (pt) 2015-12-09 2022-01-14 Scripps Research Inst Proteínas de fusão de imunoglobulina de relaxina e métodos de uso
WO2017139164A1 (en) 2016-02-12 2017-08-17 Cardiac Pacemakers, Inc. Systems and methods for patient monitoring
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
US11832970B2 (en) 2017-07-26 2023-12-05 Cardiac Pacemakers, Inc. Worsening heart failure stratification
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
ES3041602T3 (en) 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
US11246851B2 (en) 2019-01-04 2022-02-15 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
PH12021551811A1 (en) 2019-01-31 2022-03-21 Scpharmaceuticals Inc Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
JP2025528469A (ja) 2022-08-31 2025-08-28 リラクセラ ファルマツォイティッシュ ゲゼルシャフト エムベーハー ウント コー． カーゲー 免疫抑制薬及び処置方法
WO2025056188A1 (en) 2023-09-15 2025-03-20 Relaxera Pharmazeutische Gmbh & Co. Kg Relaxin medication

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
US5478807A (en) * 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
WO1995000645A2 (en) 1993-06-21 1995-01-05 Genentech, Inc. Process for producing relaxin
US5952296A (en) * 1993-07-27 1999-09-14 Bigazzi; Mario Method of using relaxin as therapeutic or preventing agent
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
CA2229479C (en) 1995-08-15 2010-03-30 Connective Therapeutics, Inc. Method of promoting angiogenesis
EP1253929B1 (en) * 2000-02-09 2007-05-23 BAS Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
DE10155843A1 (de) 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
EP1729817B1 (en) * 2004-03-30 2014-03-05 Industry-Academic Cooperation Foundation Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
US20060264367A1 (en) 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
TW200800206A (en) 2005-07-11 2008-01-01 Abbott Lab Methods for determining how to treat congestive heart failure
WO2009007848A2 (en) 2007-07-12 2009-01-15 Compugen Ltd. Bioactive peptides and method of using same
CA2724540C (en) * 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
BRPI0912559A2 (pt) 2008-05-16 2015-10-13 Corthera Inc método de tratar insuficiência cardíaca crônica

Also Published As

Publication number Publication date
PL2288373T3 (pl) 2015-11-30
WO2009140659A2 (en) 2009-11-19
US9205132B2 (en) 2015-12-08
BRPI0913011A2 (pt) 2019-09-03
US20120040903A1 (en) 2012-02-16
US20150320834A1 (en) 2015-11-12
HK1187550A1 (zh) 2014-04-11
MX2010012450A (es) 2011-03-21
CN106177914A (zh) 2016-12-07
CN103212063A (zh) 2013-07-24
JP5875646B2 (ja) 2016-03-02
EP2288373B1 (en) 2015-06-24
JP2015013870A (ja) 2015-01-22
JP2016053040A (ja) 2016-04-14
IL208992A0 (en) 2011-01-31
JP2011520918A (ja) 2011-07-21
US20130116181A1 (en) 2013-05-09
HK1139051A1 (en) 2010-09-10
EP2288373A2 (en) 2011-03-02
EA201500552A1 (ru) 2016-07-29
EA201001771A1 (ru) 2011-06-30
GB0908432D0 (en) 2009-06-24
CA2724540A1 (en) 2009-11-19
WO2009140659A3 (en) 2010-07-22
MY158327A (en) 2016-09-30
US9579363B2 (en) 2017-02-28
AR071810A1 (es) 2010-07-14
SG191587A1 (en) 2013-07-31
HK1202054A1 (en) 2015-09-18
HK1140693A1 (en) 2010-10-22
MA32389B1 (fr) 2011-06-01
NZ589009A (en) 2012-05-25
US9066916B2 (en) 2015-06-30
CN102036679A (zh) 2011-04-27
US20130210730A1 (en) 2013-08-15
HK1151229A1 (en) 2012-01-27
AU2009246114A1 (en) 2009-11-19
DK2288373T3 (en) 2015-09-28
SI2288373T1 (sl) 2015-12-31
GB2459983B (en) 2010-04-28
JP5638044B2 (ja) 2014-12-10
UA99953C2 (uk) 2012-10-25
MY159803A (en) 2017-02-15
NZ598709A (en) 2013-09-27
EP2829280A1 (en) 2015-01-28
NZ701038A (en) 2016-01-29
US8053411B2 (en) 2011-11-08
EA022948B1 (ru) 2016-03-31
GB0918132D0 (en) 2009-12-02
GB2462221B (en) 2010-09-01
TW200948353A (en) 2009-12-01
US20170151311A1 (en) 2017-06-01
US20100048475A1 (en) 2010-02-25
US8415301B2 (en) 2013-04-09
JP5651586B2 (ja) 2015-01-14
IL228244A (en) 2016-10-31
HUE025483T2 (en) 2016-02-29
AU2009246114B2 (en) 2013-01-31
ES2546287T3 (es) 2015-09-22
CR11749A (es) 2011-02-11
IL208992A (en) 2013-09-30
GB2459983A (en) 2009-11-18
PT2288373E (pt) 2015-10-19
CA2724540C (en) 2014-07-08
GB2462221A (en) 2010-02-03
TWI386202B (zh) 2013-02-21
HRP20150845T1 (hr) 2015-11-06
US20120040902A1 (en) 2012-02-16
JP2013040174A (ja) 2013-02-28
CN103212063B (zh) 2015-07-22
US8372809B2 (en) 2013-02-12
ZA201007449B (en) 2011-06-29
SG10201609580YA (en) 2016-12-29
IL247351A0 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
CY1116925T1 (el) Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
CY1121041T1 (el) Μεθοδοι αγωγης παιδιατρικων ασθενων με τη χρηση δεξμεδετομιδινης
MX336145B (es) Metodo para el tratamiento de insuficiencia cardiaca cronica.
PH12015500407B1 (en) Methods of treating hypertriglyceridemia
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
MX391565B (es) Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
ZA201804696B (en) Therapeutic use of inhibitors of t cell activation or stimulation
EP3825419A3 (en) Diagnostic, prognostic and therapeutic uses of long noncoding rnas for heart disease and regenerative medicine
CY1116344T1 (el) Κυτταρα προερχομενα απο ιστο ομφαλιου λωρου για την θεραπεια νευροπαθητικου πονου και σπαστικοτητας
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
PH12017500392A1 (en) Medical treatments based on anamorelin
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
DK1732551T3 (da) Perhexilin til behandling af kronisk hjertesvigt
EA201200319A1 (ru) Введение активированного угля при оказании неотложной помощи в случае передозировки этексилата дабигатрана
UY31499A1 (es) Nuevo uso medico de las sales de propionato 3- (2,2,2-trimetilhydrazinio) en el trtamiento de la enfermedad cardiaca isquemica
AU2016219717A1 (en) Treating dyspnea associated with acute heart failure with relaxin
WO2013177478A3 (en) Treatment method
CU20100225A7 (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
PH12016500711A1 (en) Method of treating dyspnea associated with acute heart failure
RU2010154218A (ru) Способ лечения поздней кожной порфирии у больного зависимого от гемодиализа
UA109904C2 (uk) Комбінована терапія для шкірних розладів
UA49089U (ru) Способ лечения острой сердечной недостаточности
UA40165U (ru) Способ оценки уровня кортизола у больных с ишемической болезнью сердца